期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Association of Overlapped and Un-overlapped Comorbidities with COVID-19 Severity and Treatment Outcomes: A Retrospective Cohort Study from Nine Provinces in China 被引量:10
1
作者 MA Yan ZHU Dong Shan +62 位作者 CHEN Ren Bo SHI Nan Nan liU Si Hong FAN Yi Pin WU Gui Hui YANG Pu Ye BAI Jiang Feng CHEN Hong CHEN li Ying FENG Qiao GUO Tuan Mao HOU Yong HU Gui Fen HU Xiao Mei HU Yun Hong HUANG Jin HUANG Qiu Hua HUANG Shao Zhen JI liang JIN Hai Hao LEI Xiao li Chun Yan li Min Qing li Qun Tang li Xian Yong liU Hong De liU Jin Ping liU Zhang MA Yu Ting MAO Ya MO liu Fen NA Hui WANG Jing Wei SONG Fang li SUN sheng WANG Dong Ting WANG Ming Xuan WANG Xiao Yan WANG Yin Zhen WANG Yu Dong WU Wei WU Lan Ping XIAO Yan Hua XIE Hai Jun XU Hong Ming XU Shou Fang XUE Rui Xia YANG Chun YANG Kai Jun yuan sheng li ZHANG Gong Qi ZHANG Jin Bo ZHANG lin Song ZHAO Shu Sen ZHAO Wan Ying ZHENG Kai ZHOU Ying Chun ZHU Jun Teng ZHU Tian Qing ZHANG Hua Min WANG Yan Ping WANG Yong Yan 《Biomedical and Environmental Sciences》 SCIE CAS CSCD 2020年第12期893-905,共13页
Objective Several COVID-19 patients have overlapping comorbidities. The independent role of each component contributing to the risk of COVID-19 is unknown, and how some non-cardiometabolic comorbidities affect the ris... Objective Several COVID-19 patients have overlapping comorbidities. The independent role of each component contributing to the risk of COVID-19 is unknown, and how some non-cardiometabolic comorbidities affect the risk of COVID-19 remains unclear.Methods A retrospective follow-up design was adopted. A total of 1,160 laboratory-confirmed patients were enrolled from nine provinces in China. Data on comorbidities were obtained from the patients’ medical records. Multivariable logistic regression models were used to estimate the odds ratio(OR) and 95% confidence interval(95% CI) of the associations between comorbidities(cardiometabolic or non-cardiometabolic diseases), clinical severity, and treatment outcomes of COVID-19.Results Overall, 158(13.6%) patients were diagnosed with severe illness and 32(2.7%) had unfavorable outcomes. Hypertension(2.87, 1.30–6.32), type 2 diabetes(T2 DM)(3.57, 2.32–5.49),cardiovascular disease(CVD)(3.78, 1.81–7.89), fatty liver disease(7.53, 1.96–28.96), hyperlipidemia(2.15, 1.26–3.67), other lung diseases(6.00, 3.01–11.96), and electrolyte imbalance(10.40, 3.00–26.10)were independently linked to increased odds of being severely ill. T2 DM(6.07, 2.89–12.75), CVD(8.47,6.03–11.89), and electrolyte imbalance(19.44, 11.47–32.96) were also strong predictors of unfavorable outcomes. Women with comorbidities were more likely to have severe disease on admission(5.46,3.25–9.19), while men with comorbidities were more likely to have unfavorable treatment outcomes(6.58, 1.46–29.64) within two weeks.Conclusion Besides hypertension, diabetes, and CVD, fatty liver disease, hyperlipidemia, other lung diseases, and electrolyte imbalance were independent risk factors for COVID-19 severity and poor treatment outcome. Women with comorbidities were more likely to have severe disease, while men with comorbidities were more likely to have unfavorable treatment outcomes. 展开更多
关键词 COMORBIDITIES COVID-19 SEVERITY GENDER Age Treatment outcome
下载PDF
二甲双胍联合不同剂量克罗米芬治疗多囊卵巢综合征的效果分析 被引量:5
2
作者 张晓燕 袁盛丽 韩晖 《中国妇幼卫生杂志》 2019年第3期32-35,共4页
目的探究二甲双胍联合不同剂量克罗米芬治疗多囊卵巢综合征(PCOS)不孕症患者的临床效果。方法回顾性分析襄阳市妇幼保健院2015年8月-2018年4月的PCOS不孕症患者,研究组接受二甲双胍+克罗米芬100 mg、对照组接受二甲双胍+克罗米芬50 mg... 目的探究二甲双胍联合不同剂量克罗米芬治疗多囊卵巢综合征(PCOS)不孕症患者的临床效果。方法回顾性分析襄阳市妇幼保健院2015年8月-2018年4月的PCOS不孕症患者,研究组接受二甲双胍+克罗米芬100 mg、对照组接受二甲双胍+克罗米芬50 mg促排卵。比较两组患者h CG日血清LH、E2水平、成熟卵泡数和内膜厚度,以及排卵率、临床妊娠率、早期流产率。结果研究组和对照组分别纳入218例、240例患者。两组患者h CG日血清LH、子宫内膜厚度,早期流产率差异无统计学意义(P>0.05)。研究组h CG日血清E2水平、成熟卵泡数、排卵率和临床妊娠率显著高于对照组,差异有统计学意义(P<0.05)。结论二甲双胍联合克罗米芬每天100 mg比每天50 mg治疗PCOS不孕症患者显著增高h CG日E2水平、成熟卵泡数、排卵率和临床妊娠率。 展开更多
关键词 多囊卵巢综合征 二甲双胍 克罗米芬
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部